Epstein Secrets

et, 3 ni floor San Francisco, CA 94103 Dear Mr. Tamaru: We have completed our analysis of the fair market value of the common equity of AliphCom ("Aliph" or the "Company") on a per share basis (the "Subject Interest") as of June 20, 2011 (the "Valuation Date"). We understand that our valuation of th

value for the Company's equity. Please see Exhibits F and G for further details related to our analysis utilizing the Income Approach. • PCMMM of the Market Approach. This methodology was considered as a reasonableness check in our analysis, but ultimately not relied upon due to differences between the Company an

et, 3 ni floor San Francisco, CA 94103 Dear Mr. Tamaru: We have completed our analysis of the fair market value of the common equity of AliphCom ("Aliph" or the "Company") on a per share basis (the "Subject Interest") as of June 20, 2011 (the "Valuation Date"). We understand that our valuation of th

value for the Company's equity. Please see Exhibits F and G for further details related to our analysis utilizing the Income Approach. • PCMMM of the Market Approach. This methodology was considered as a reasonableness check in our analysis, but ultimately not relied upon due to differences between the Company an

et, 3 ni floor San Francisco, CA 94103 Dear Mr. Tamaru: We have completed our analysis of the fair market value of the common equity of AliphCom ("Aliph" or the "Company") on a per share basis (the "Subject Interest") as of June 20, 2011 (the "Valuation Date"). We understand that our valuation of th

value for the Company's equity. Please see Exhibits F and G for further details related to our analysis utilizing the Income Approach. • PCMMM of the Market Approach. This methodology was considered as a reasonableness check in our analysis, but ultimately not relied upon due to differences between the Company an